Skip to content

Observational Study on the Impact of NLRP3 Inflammasome Pathway on Coronary Microcirculatory Dysfunction in Patients with Non-obstructive Ischemic Coronary Heart Disease Using Flash caIMR System and Targeted Metabolomics Technology

Observational Study on the Impact of NLRP3 Inflammasome Pathway on Coronary Microcirculatory Dysfunction in Patients with Non-obstructive Ischemic Coronary Heart Disease Using Flash caIMR System and Targeted Metabolomics Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105134
Enrollment
Unknown
Registered
2025-06-30
Start date
2025-07-05
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-obstructive Ischemic Coronary Heart Disease

Interventions

INOCA group:none
control group:none

Sponsors

Department of Cardiology, Beijing Jishuitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Patients with angina pectoris hospitalized in the Department of Cardiology and CCU of our hospital who are planned for coronary evaluation. 2. Age>=18 years old. 3. The quality of coronary angiography images meets the measurement requirements of the Flash caIMR system software. 4. Patients/family members have signed written informed consent for research ethical approval..

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. History of previous PCI intervention or coronary angiography showing at least one major coronary artery with a luminal stenosis>=50%; 2. Poor quality of coronary angiography images considered to affect measurements by the Flash caIMR system software; 3. Other organic heart diseases such as congenital heart disease, rheumatic heart disease, heart valve disease, cardiomyopathy, and heart failure; 4. Severe liver or kidney function damage, active rheumatic arthritis, active tuberculosis, autoimmune diseases, mental illness, malignant tumors, or organ transplantation; 5. History of infection, fever, trauma, burns, or surgery within the past month; 6. Acute stroke within the past six months; 7. Participation in other clinical trials within the past month; 8. Women who are pregnant or breastfeeding; 9. Individuals considered unsuitable for clinical trials by the researchers.

Design outcomes

Primary

MeasureTime frame
coronary artery index of microvascular resistance ;

Secondary

MeasureTime frame
coronary artery flow reserve fraction;

Countries

China

Contacts

Public ContactLiu Wei

Beijing Jishuitan Hospital, Capital Medical University

liuwei525@hotmail.com+86 189 1093 8225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026